NuVasive, Inc. (NASDAQ:NUVA)‘s stock had its “outperform” rating restated by Cowen and Company in a research note issued to investors on Monday. They currently have a $83.00 target price on the medical device company’s stock. Cowen and Company’s price target would indicate a potential upside of 43.60% from the company’s current price.

NUVA has been the topic of a number of other reports. Needham & Company LLC reiterated a “hold” rating on shares of NuVasive in a research note on Friday, July 28th. Royal Bank Of Canada increased their price objective on shares of NuVasive from $76.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, June 6th. Barclays PLC restated a “buy” rating and issued a $80.00 price target on shares of NuVasive in a research report on Wednesday, August 2nd. Piper Jaffray Companies restated an “overweight” rating and issued a $90.00 price target on shares of NuVasive in a research report on Wednesday, August 9th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $79.00 price target on shares of NuVasive in a research report on Sunday, July 30th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $80.42.

Shares of NuVasive (NASDAQ:NUVA) traded down 1.16% during midday trading on Monday, reaching $57.80. 1,132,705 shares of the company traded hands. NuVasive has a 12 month low of $56.70 and a 12 month high of $81.68. The firm has a market capitalization of $2.94 billion, a P/E ratio of 91.02 and a beta of 1.08. The company has a 50 day moving average of $63.17 and a 200 day moving average of $72.31.

NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 EPS for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.02. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The firm had revenue of $260.60 million for the quarter, compared to the consensus estimate of $261.95 million. During the same period in the prior year, the firm posted $0.40 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts predict that NuVasive will post $2.00 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “NuVasive’s (NUVA) Outperform Rating Reiterated at Cowen and Company” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/09/18/nuvasives-nuva-outperform-rating-reiterated-at-cowen-and-company.html.

In related news, CEO Gregory T. Lucier bought 5,000 shares of the stock in a transaction on Thursday, August 17th. The shares were purchased at an average price of $66.22 per share, with a total value of $331,100.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Peter Michael Leddy bought 7,850 shares of the stock in a transaction on Tuesday, August 1st. The shares were bought at an average cost of $63.88 per share, for a total transaction of $501,458.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 14,850 shares of company stock worth $955,598. Corporate insiders own 1.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the business. Miles Capital Inc. increased its stake in NuVasive by 0.3% during the 1st quarter. Miles Capital Inc. now owns 3,118 shares of the medical device company’s stock valued at $233,000 after buying an additional 8 shares during the period. Hanseatic Management Services Inc. increased its stake in NuVasive by 0.3% during the 2nd quarter. Hanseatic Management Services Inc. now owns 14,868 shares of the medical device company’s stock valued at $1,144,000 after buying an additional 39 shares during the period. Teacher Retirement System of Texas increased its stake in NuVasive by 1.0% during the 2nd quarter. Teacher Retirement System of Texas now owns 4,040 shares of the medical device company’s stock valued at $311,000 after buying an additional 40 shares during the period. US Bancorp DE increased its stake in NuVasive by 1.7% during the 1st quarter. US Bancorp DE now owns 2,401 shares of the medical device company’s stock valued at $180,000 after buying an additional 41 shares during the period. Finally, Northwestern Mutual Investment Management Company LLC increased its stake in NuVasive by 0.5% during the 1st quarter. Northwestern Mutual Investment Management Company LLC now owns 8,720 shares of the medical device company’s stock valued at $651,000 after buying an additional 43 shares during the period.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Stock Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related stocks with our FREE daily email newsletter.